GlassScriptPhysician profile
Sandra J Mccoy
NPI 1083645998
$14,364.32
in general payments reported to CMS, 2019-2025
41 companies · $3,308 in 2025
The $3,308 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,803 · 2022: $2,374 · 2023: $2,875 · 2024: $3,003 · 2025: $3,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,186.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,584.82 | 2021-2025 | Evenity, Repatha, Krystexxa |
| Novo Nordisk INC | $1,984.93 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,401.04 | 2021-2025 | Mounjaro, Jardiance, Kisunla |
| Astrazeneca Pharmaceuticals LP | $1,275.78 | 2021-2024 | Farxiga, Airsupra |
| Dexcom, INC. | $584.57 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Bayer Healthcare Pharmaceuticals INC. | $506.77 | 2024-2025 | |
| Abbott Laboratories | $450.48 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $380.11 | 2022-2024 | Quviviq |
| Kyowa Kirin, INC. | $345.64 | 2023-2025 | Crysvita |
| Genzyme Corporation | $321.82 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $281.55 | 2024-2025 | Voquezna |
| Abbvie INC. | $256.15 | 2022-2025 | |
| Glaxosmithkline, LLC. | $222.51 | 2024-2025 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $215.12 | 2021-2023 | Gattex, Trintellix |
| Janssen Pharmaceuticals, INC | $210.91 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.